The report "Global Mild Traumatic Brain Injury Treatment Market, By Device Type (Imaging Devices (Computed Tomography Devices, Magnetic Resonance Imaging, X-Ray, and Others), Clinical Examination Devices, and Monitoring Devices (Invasive Monitoring Devices and Non-Invasive Monitoring Devices)), By Technique (Intracranial Pressure Monitoring (ICP) and Partial Pressure of Oxygen in Brain Tissue (pBrO2)), By End-User (Hospitals, Diagnostic Imaging Centers, and Others), and Region - Global Forecast to 2029" Global mild traumatic brain injury treatment market is projected to grow from US$ XX billion in 2019 to US$ XX billion by 2029. Global mild traumatic brain injury treatment market is driven by increasing number of road accidents, coupled with growing number of vulnerable aging population. In addition, growing research activities on diagnosis management and large number of new pipeline drugs are further propelling the growth of the global mild traumatic brain injuries treatment market. Extensive R&D by the U.S. Food and Drug Administration (FDA) scientists in order to study various biomarkers of brain imaging, bio fluid and physical indicators for detection of traumatic brain injuries (TBI) is going on. This is expected to change the treatment pattern of TBI in patients with severe brain injuries which in turn boosting growth of the global market. The molecular targeted therapies such as BHR-100, a progesterone drug produced by BHR Pharma, LLC, rhuEpo, and a recombinant human erythropoietin is anticipated to drive growth of the global market over the forecast period. Nevertheless, conducting large number of clinical trials worldwide in order to develop effective therapies for TBI is creating opportunities for growth of the global market.

Key Highlights:

• On December 2019, Teva Pharmaceutical Industries Ltd. has announced that U.S. Food and Drug Administration (FDA) have accepted its review for company’s Biologics License Application (BLA) for fremanezumab. It is an anti-calcitonin gene-related peptide monoclonal antibody used for ths treatment of migraine.
• On March 2018, Vasopharm has provided an update on phase III traumatic brain injury trial. This study enrolls 220 patients who have received an intra-cranial pressure probe and who have suffered from moderate to severe TBI resulting in hospitalisation.

Key Market Insights from the report:          

The global mild traumatic brain injury treatment market accounted for US$ XX billion in 2019 and is projected to register a moderate CAGR of XX% over the forecast period. The market report has been segmented on the basis of device type, technique, end-user, and region.

• By device type, the global mild traumatic brain injury treatment market is segmented into imaging devices, clinical examination devices, and monitoring devices. Imaging devices type segment is further bifurcated into computed tomography devices, magnetic resonance imaging, x-ray, and others. Monitoring devices type segment is further classified into invasive monitoring devices and non-invasive monitoring devices. The imaging devices segment hold the largest share in 2016, due to non-invasive technique for monitoring of traumatic brain injury along with its higher preference among health care providers and patients.
• By technique, the global mild traumatic brain injury treatment market is segmented into intracranial pressure monitoring (ICP) and partial pressure of oxygen in brain tissue (pBrO2). In 2016, the intracranial pressure monitoring technique segment holded highest market share, owing to increase number of devices approved for this technique along with the introduction of new non-invasive monitoring devices by market players.
• By end-user, the global mild traumatic brain injury treatment market is bifurcated into hospitals, diagnostic imaging centers, and others.
•  By region, North America holds the major share of global mild traumatic brain injuries treatment market owing to increasing number of TBI (traumatic brain injury) patients, and increasing research and development activity on diagnosis management. Europe accounts for the second largest market share of the global mild traumatic brain injuries treatment market. This is attributed due to increasing government initiatives to funding for traumatic brain injuries project and growing incidence in elderly patients, coupled with increasing road traffic accidents. In Asia-Pacific the growth of the global mild traumatic brain injuries treatment market is due to growing number of neurologist centers and trauma centers and increasing incidences of road accident.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on " Global Mild Traumatic Brain Injury Treatment Market”, By Device Type (Imaging Devices (Computed Tomography Devices, Magnetic Resonance Imaging, X-Ray, and Others), Clinical Examination Devices, and Monitoring Devices (Invasive Monitoring Devices and Non-Invasive Monitoring Devices)), By Technique (Intracranial Pressure Monitoring (ICP) and Partial Pressure of Oxygen in Brain Tissue (pBrO2)), By End-User (Hospitals, Diagnostic Imaging Centers, and Others), and by Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa)- forecast till 2029

To know the upcoming trends and insights prevalent in this market, click the link below:

https://prophecymarketinsights.com/market_insight/Global-Mild-Traumatic-Brain-Injury-2656

The prominent player operating in the global mild traumatic brain injury treatment market includes Neuren Pharmaceuticals Ltd, TEVA Pharmaceutical Industries Ltd., Grace Laboratories LLC., NeuroScience Pharmaceuticals, Tenax Therapeutics, Inc., IschemixInc, Vasopharm GmbH, AmarantusBioScience Holdings, Silver Creek Pharmaceuticals Inc, Stemedica Cell Technologies Inc, and Banayan Biomarkers Inc.